-

Miach Orthopaedics Names Jamal Rushdy President & CEO

Patrick McBrayer Stepping Down Following Transformative Tenure That Positioned Company for Next Phase of Growth

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced Jamal Rushdy has been selected as the company’s next president and CEO. Patrick McBrayer is stepping down from the role following a planned leadership transition conducted in partnership with the board of directors. McBrayer will remain president and CEO until Rushdy assumes the role on May 18.

“Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant,” said Joyce Erony, chairwoman of the Miach board and managing partner at Amzak Health. “Under his leadership, the company has established a strong presence in ACL restoration, with the BEAR Implant now used by more than 750 surgeons and to treat over 9,000 patients. Jamal is the right person to build on that foundation and guide Miach through its next phase of growth.”

Rushdy brings nearly 30 years of experience in the medical device industry, with deep expertise in orthopedics, sports medicine, and regenerative medicine. He most recently served as CEO of Arcuro Medical and previously led Collagen Solutions. Over the course of his career, he has raised significant operating capital and led organizations across various stages of growth, from early-stage ventures to high-growth established companies. He has also held senior leadership roles at Tornier and DJO (now Enovis) and was a founding executive of three medtech companies with multiple successful exits.

“Miach has built strong momentum with differentiated technology and compelling clinical evidence behind the BEAR Implant,” Rushdy said. “The opportunity now is to expand use and advance new indications, with the goal of helping people with ACL tears return to an active lifestyle while preserving long-term knee health. I’m excited to work with the Miach team and the orthopedic community to bring the benefits of the BEAR Implant to even more people, and I thank Patrick for his support.”

The BEAR Implant is the first disruptive technology in ACL tear treatment in more than 30 years. The implant enables a torn ACL to heal and restores the natural function of the knee. It is a paradigm shift from the current standard of care – reconstruction that replaces the ACL with a graft.

McBrayer joined Miach in 2022 and played a pivotal role in strengthening the company’s foundation and positioning it for growth. During his tenure, Miach secured more than $60 million in funding, expanded commercial adoption of the BEAR Implant, and achieved FDA approval of key label updates to enable use in children and adolescents of any age and for partial ACL tears, as well as to include reduced risk of developing radiographically confirmed post-traumatic osteoarthritis (PTOA). He also helped build the company’s executive leadership team and shape its culture during his successful tenure.

“Miach is entering its next chapter with strong momentum, and it has been an honor to lead the company’s efforts to transform the treatment of ACL tears over the past several years,” McBrayer said. “What this team has accomplished, from bringing the BEAR Implant into broader clinical use to expanding its adoption among surgeons, has been incredibly meaningful. I’m beyond proud of what this team has built and excited about the impact Miach will continue to have in the years ahead.”

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc., is a privately held company located in Westborough, Massachusetts, dedicated to developing surgical implants to facilitate connective tissue restoration. The company’s initial focus is the BEAR® Implant, which represents a paradigm shift in the treatment of ACL tears. For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Facebook, Instagram, TikTok and LinkedIn.

BEAR® Implant is a registered trademark of Miach Orthopaedics.

Contacts

MEDIA CONTACT:
Joni Ramirez
M+
joni@mplushealth.com
323-532-0746

Miach Orthopaedics, Inc.


Release Summary
Jamal Rushdy has been selected as Miach Orthopaedics' next president and CEO. He will assume the role on May 18.
Release Versions

Contacts

MEDIA CONTACT:
Joni Ramirez
M+
joni@mplushealth.com
323-532-0746

Social Media Profiles
More News From Miach Orthopaedics, Inc.

FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Miach Orthopaedics' BEAR Implant label updated to include significantly lower risk of post-traumatic osteoarthritis following ACL injury....

Real-World Evidence for Miach Orthopaedics’ BEAR® Implant Highlighted at AOSSM 2025

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Miach Orthopaedics’ presents real-world evidence on BEAR Implant highlighting one- and two-year results from the Bridge Registry study at AOSSM 2025....

BEAR MOON Study of Miach Orthopaedics’ BEAR® Implant Completes Enrollment

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Miach Orthopaedics completes enrollment for BEAR MOON study comparing the BEAR Implant to ACL reconstruction for complete ACL tears....
Back to Newsroom